Adenosine A1 receptors link to smooth muscle contraction via CYP4a, protein kinase C-α, and ERK1/2

J Cardiovasc Pharmacol. 2013 Jul;62(1):78-83. doi: 10.1097/FJC.0b013e3182919591.

Abstract

Adenosine A1 receptor (A1AR) activation contracts smooth muscle, although signaling mechanisms are not thoroughly understood. Activation of A1AR leads to metabolism of arachidonic acid, including the production of 20-hydroxyeicosatetraenoic acid (20-HETE) by cytochrome P4504a (CYP4a). The 20-HETE can activate protein kinase C-α (PKC-α), which crosstalks with extracellular signal-regulated kinase (ERK1/2) pathway. Both these pathways can regulate smooth muscle contraction, we tested the hypothesis that A1AR contracts smooth muscle through a pathway involving CYP4a, PKC-α, and ERK1/2. Experiments included isometric tension recordings of aortic contraction and Western blots of signaling molecules in wild type (WT) and A1AR knockout (A1KO) mice. Contraction to the A1-selective agonist 2-chloro-N cyclopentyladenosine (CCPA) was absent in A1KO mice aortae, indicating the contractile role of A1AR. Inhibition of CYP4a (HET0016) abolished 2-chloro-N cyclopentyladenosine-induced contraction in WT aortae, indicating a critical role for 20-HETE. Both WT and A1KO mice aortae contracted in response to exogenous 20-HETE. Inhibition of PKC-α (Gö6976) or ERK1/2 (PD98059) attenuated 20-HETE-induced contraction equally, suggesting that ERK1/2 is downstream of PKC-α. Contractions to exogenous 20-HETE were significantly less in A1KO mice; reduced protein levels of PKC-α, p-ERK1/2, and total ERK1/2 supported this observation. Our data indicate that A1AR mediates smooth muscle contraction via CYP4a and a PKC-α-ERK1/2 pathway.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Adenosine A1 Receptor Agonists / pharmacology
  • Animals
  • Blotting, Western
  • Carbazoles / pharmacology
  • Cytochrome P-450 CYP4A / antagonists & inhibitors
  • Cytochrome P-450 CYP4A / physiology*
  • Enzyme Inhibitors / pharmacology
  • Female
  • Flavonoids / pharmacology
  • Hydroxyeicosatetraenoic Acids / pharmacology
  • Isometric Contraction / drug effects
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / physiology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Muscle Contraction / drug effects*
  • Muscle, Smooth, Vascular / drug effects*
  • Protein Kinase C-alpha / physiology*
  • Receptor, Adenosine A1 / drug effects
  • Receptor, Adenosine A1 / physiology*

Substances

  • Adenosine A1 Receptor Agonists
  • Carbazoles
  • Enzyme Inhibitors
  • Flavonoids
  • Hydroxyeicosatetraenoic Acids
  • Receptor, Adenosine A1
  • Go 6976
  • 2-chloro-N(6)cyclopentyladenosine
  • 20-hydroxy-5,8,11,14-eicosatetraenoic acid
  • Cytochrome P-450 CYP4A
  • Protein Kinase C-alpha
  • Adenosine
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one